Abstract
NLC is a next-generation lipid nanocarrier, which holds many advantages over other colloidal lipid carrier systems like higher drug loading, better and controlled release and enhanced stability. Owing to the unique structural composition, i.e. crystallized solid and liquid lipid blend, it offers excellent biocompatibility and higher permeation across physiological membranes like BBB. Moreover, the surface of NLC can easily be modified with target-specific ligands, proteins, peptides, etc. which makes it a potential candidate for brain targeting of CNS acting drugs. NLC has found various applications for the treatment of various CNS disorders including Alzheimer’s disease, Parkinson’s disease, schizophrenia, epilepsy, migraine, cerebral ischemia, etc. Among these, the application of NLC towards the treatment of AD has been well-explored in the past two decades. In this piece of work, we have discussed the types of NLC, its composition, fabrication techniques, characterization, stability profile and application in the treatment of AD.
Keywords: Nanostructured lipid carrier, lipid, brain, BBB, Alzheimer's disease, fabrication techniques.
[http://dx.doi.org/10.1016/j.canlet.2012.07.006 ] [PMID: 22796606]
[http://dx.doi.org/10.1016/j.jconrel.2018.05.011] [PMID: 29772289]
[http://dx.doi.org/10.1016/j.colsurfb.2013.03.037] [PMID: 23711779]
[http://dx.doi.org/10.1016/j.colsurfb.2014.01.055] [PMID: 24607519]
[PMID: 29968543]
[http://dx.doi.org/10.1016/j.jconrel.2017.08.033]
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[http://dx.doi.org/10.3109/1061186X.2014.934688] [PMID: 25012065]
[http://dx.doi.org/10.3389/fphar.2018.00802] [PMID: 30154715]
[http://dx.doi.org/10.4103/0975-7406.130965] [PMID: 25035633]
[http://dx.doi.org/10.1016/B978-0-323-32889-0.00014-5]
[http://dx.doi.org/10.2147/IJN.S138624] [PMID: 28814860]
[http://dx.doi.org/10.3389/fphar.2015.00286] [PMID: 26648870]
[http://dx.doi.org/10.4103/0110-5558.76435] [PMID: 22247876]
[http://dx.doi.org/10.4103/0250-474X.57282] [PMID: 20502539]
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[http://dx.doi.org/10.2174/1872210511307010041] [PMID: 22946628]
[http://dx.doi.org/10.1186/1556-276X-8-102] [PMID: 23432972]
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i6.10] [PMID: 20402623]
[http://dx.doi.org/10.3109/10717544.2013.838077] [PMID: 24156390]
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.005] [PMID: 28495500]
[http://dx.doi.org/10.1016/S0169-409X(00)00103-4] [PMID: 11104900]
[http://dx.doi.org/10.2174/1574888X13666181002161700] [PMID: 30280676]
[http://dx.doi.org/10.1080/17425247.2016.1178237] [PMID: 27073977]
[PMID: 18203427]
[http://dx.doi.org//10.1208/s12249-010-9563-0] [PMID: 21174180]
[http://dx.doi.org/10.3109/1061186X.2012.716845] [PMID: 22931500]
[http://dx.doi.org/10.1016/j.biopha.2018.04.055]
[http://dx.doi.org/10.3390/pharmaceutics9020012]] [PMID: 28346375]
[http://dx.doi.org/10.1002/jat.3213] [PMID: 26212026]
[http://dx.doi.org/10.1021/jf305143k] [PMID: 23362941]
[http://dx.doi.org/10.1073/pnas.88.24.11460] [PMID: 1763060]
[http://dx.doi.org/10.1016/0169-409X(95)00028-6]
[http://dx.doi.org/10.1016/j.yexmp.2008.12.004] [PMID: 19186176]
[http://dx.doi.org/10.1016/j.msec.2012.04.017] [PMID: 24364934]
[http://dx.doi.org/10.1080/02652040500435295] [PMID: 16854814]
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.005] [PMID: 20471464]
[http://dx.doi.org/10.1016/j.ijpharm.2007.05.060] [PMID: 17651933]
[http://dx.doi.org/10.1016/S0378-5173(02)00081-9] [PMID: 12052697]
[http://dx.doi.org/10.1080/02652040500162436] [PMID: 16361193]
[PMID: 22615636]
[http://dx.doi.org/10.3109/02652048.2010.513456] [PMID: 21034365]
[http://dx.doi.org/10.1016/j.colsurfb.2005.08.005] [PMID: 16198092]
[http://dx.doi.org/10.1016/j.ijpharm.2013.03.034] [PMID: 23535345]
[http://dx.doi.org/10.1016/j.jconrel.2005.07.023]
[http://dx.doi.org/10.1016/j.ejpb.2011.04.009]
[http://dx.doi.org/10.1016/j.colsurfb.2013.08.032] [PMID: 24060926]
[http://dx.doi.org/10.1517/17425247.2012.673278] [PMID: 22439808]
[http://dx.doi.org/10.1016/S0169-409X(01)00105-3] [PMID: 11311991]
[http://dx.doi.org/10.4103/1735-5362.235156] [PMID: 30065762]
[http://dx.doi.org/10.1111/jphp.12262] [PMID: 24824413]
[http://dx.doi.org/10.1016/j.ifset.2013.03.002]
[http://dx.doi.org/10.1016/j.jpba.2013.08.018] [PMID: 24012480]
[http://dx.doi.org/10.1016/j.partic.2007.12.002]
[http://dx.doi.org/10.1146/annurev-pharmtox-010611-134623] [PMID: 22035254]
[http://dx.doi.org/10.1517/17425247.2014.950564] [PMID: 25138827]
[http://dx.doi.org/10.1007/s11095-005-7148-5] [PMID: 16132349]
[http://dx.doi.org/10.2147/IJN.S108694] [PMID: 27555771]
[http://dx.doi.org/10.1016/j.micron.2012.07.008]
[http://dx.doi.org/10.1016/j.ijpharm.2012.09.018] [PMID: 22989983]
[http://dx.doi.org/10.1016/j.ijpharm.2006.01.022] [PMID: 16574354]
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.067] [PMID: 25445970]
[http://dx.doi.org/10.1016/j.msec.2014.12.012] [PMID: 25579930]
[http://dx.doi.org/10.1080/02652048.2017.1284276] [PMID: 28097914]
[http://dx.doi.org//10.1016/j.nano.2015.09.004] [PMID: 26410277]
[http://dx.doi.org/10.1016/j.addr.2007.04.013] [PMID: 17658653]
[http://dx.doi.org/10.1186/1476-511X-11-159] [PMID: 23167765]
[http://dx.doi.org/10.3109/10837450903013568] [PMID: 19552542]
[http://dx.doi.org/10.1016/j.colsurfb.2013.12.012] [PMID: 24445002]
[http://dx.doi.org/10.1016/j.ejphar.2017.09.043] [PMID: 28978455]
[http://dx.doi.org/10.1016/j.ijpharm.2016.10.024] [PMID: 27756627]
[http://dx.doi.org/10.1080/21655979.2016.1197029] [PMID: 27710431]
[http://dx.doi.org/10.1016/j.ijpharm.2016.04.033] [PMID: 27094357]